Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting Antibodies

• DOI: 10.2967/jnumed.111.092833
• Publication Date: 2011-10-12T01:59:46Z
• Authors: Anton G.T. Terwis...; Gooitzen M. van Dam; Wouter B. Nagengast; Vasilis Ntziachri...; Harry Hollema; Jennifer L. Herek; Carolien P. Schröder; Jos G.W. Kosterink; Marjolijn N. Lub-...; Elisabeth G.E. de...
• Keywords: Biodistribution; Fluorescence-lifetime imaging microscopy; Ex vivo

Fluorescence imaging is currently attracting much interest as a method for intraoperative tumor detection, but most current tracers lack specificity. Therefore, this technique can be further improved by tumor-specific detection. With tumor-targeted antibodies bound to radioactive label, SPECT or PET feasible in the clinical setting. The aim of present study was apply antibody-based detection optical imaging, using preclinical vivo mouse models. <b>Methods:</b> Anti–vascular endothelial growth factor (VEGF) antibody bevacizumab and anti–human epidermal receptor (HER) 2 trastuzumab were labeled with near-infrared (NIR) fluorescence dye IRDye 800CW. Tumor uptake fluorescent their ⁸⁹Zr-labeled counterparts determined human xenograft–bearing athymic mice during 1 wk after tracer injection, followed ex biodistribution pathologic examination. Intraoperative VEGF- HER2-positive lesions performed subcutaneous tumors intraperitoneal dissemination <b>Results:</b> Tumor-to-background ratios, 1.93 ± 0.40 2.92 0.29 on day 6 injection. Real-time detected at even submillimeter level These results supported standard histology, immunohistochemistry, microscopy analyses. <b>Conclusion:</b> NIR fluorescence–labeled targeting VEGF HER2 used highly specific sensitive vivo. findings encourage future studies intraoperative-guided surgery cancer patients.